BiotechTube
Lumos Diagnostics

Lumos Diagnostics

LDX.AX
United States
lumosdiagnostics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

LDX.AX · Stock Price

AUD 0.15+0.15 (+0.00%)
Market Cap: $100.4M

Historical price data

Overview

Lumos Diagnostics is a specialized diagnostics company with a mission to simplify clinical decisions through rapid, actionable tests at the point of care. The company has achieved significant commercial milestones, including U.S. FDA 510(k) clearance with CLIA waiver for its flagship FebriDx® test, unlocking a major market opportunity, and has secured its largest-ever order for the product. Its strategy combines proprietary product commercialization with a high-margin CDMO service business, utilizing a flexible technology platform centered on lateral flow assays and the Leelu digital reader.

Infectious DiseaseInflammatory Disease

Technology Platform

Integrated lateral flow assay (LFA) development and manufacturing platform coupled with the proprietary, customizable Leelu digital reader, which adds quantitative data capture and connectivity to rapid POC tests.

Funding History

2
Total raised:$35M
IPO$20M
Series A$15M

Opportunities

The recent FDA CLIA waiver for FebriDx unlocks a major U.S.
market opportunity estimated at over $1 billion in the antibiotic stewardship segment.
Additionally, the growing demand for outsourced development in diagnostics presents a scalable, high-margin revenue stream through its CDMO services.

Risk Factors

Key risks include commercial execution risk in capitalizing on the FebriDx CLIA waiver, concentration risk on the success of a single flagship product, and intense competition from larger, well-funded diagnostics companies in both proprietary and CDMO markets.

Competitive Landscape

Lumos faces competition from large diagnostics firms (e.g., Abbott, Roche) in its proprietary test markets and from specialized CDMOs in its service business. Its differentiated dual-biomarker approach (FebriDx) and integrated assay-plus-reader platform provide competitive edges in specific niches.

More companies in Diagnostics & Precision Medicine →More companies in United States →